NEUCHATEL, Switzerland-- (BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the CE marking of SpHb ®, noninvasive and continuous hemoglobin monitoring, for neonatal and infant patients (< 3 kg).

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of a retrospective study published in the Journal of Clinical Monitoring and Computing in which Dr. Ayten ...

Noting that anemia and blood transfusion are related to morbidity and mortality in surgical patients, Dr. Nakamori and colleagues sought to determine the utility of SpHb monitoring in avoiding ...

Noting that traditional methods of measuring hemoglobin and estimating blood loss as part of perioperative blood transfusion management are “time consuming” and may cause delays in decision making, ...

Masimo presented its study on the noninvasive and continuous total hemoglobin monitoring technology at the Society for Technology in Anesthesia’s annual meeting. The device is designed to help ...

Connected care company Masimo has landed and expanded FDA clearance for its O3 Regional Oximeter, for both somatic applications and monitoring changes in the cerebral hemoglobin. It specifically ...

A pullback in spending by hospitals is being felt at Irvine’s Masimo Corp. The maker of patient monitors and supplies said earlier this month that it was cutting its full-year sales guidance for a new ...

Masimo MASI recently secured FDA 510(k) clearance for expanded indications of its O3 Regional Oximetry with delta hemoglobin parameters. These parameters track relative changes in hemoglobin levels, ...

Now Available for Both Cerebral and Somatic Applications and for All Patient Populations, O3’s Delta Hemoglobin Parameters Offer Clinicians Additional Insight Into Changes in Tissue Oxygen Saturation ...

Nov 15 (Reuters) - Masimo Corp , a maker of non-invasive patient monitoring products, told U.S. regulators that it received allegations about the safety and efficacy of its hemoglobin testing products ...